Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

Corgenix transfers viral diagnostics business to Zalgen Labs

MDBR Staff Writer Published 23 August 2016

Corgenix Medical has transferred its viral hemorrhagic fever diagnostics business to Zalgen Labs, which is a member of the Viral Hemorrhagic Fever Consortium (VHFC).

VHFC is engaged in the development of novel diagnostic and immunotherapeutic products for biothreat agents and emerging pathogens

Zalgen has received Corgenix products, including ReEBOV antigen rapid test and ReLASV antigen rapid test for Lassa fever diagnosis.

ReEBOV is claimed to be the first rapid diagnostic test (RDT) and the first immunoassay authorized for emergency use by the FDA for the presumptive detection of Ebola virus.

It is also the first listed test for procurement by the World Helath Organization (WHO) under the emergency use assessment and listing procedure.

ReLASV is said to be the first RDT for Lassa virus, which received CE mark approval. Zalgen has also received other products for research use only.

In addition, Zalgen has received an existing small business innovation research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

The grant will be used for development of recombinant antigen diagnostics for filoviruses.

Zalgen has also opened an advanced product development center in the Fitzsimons Bioscience Park Center on the University of Colorado Anschutz Medical Campus in Aurora, US.

Zalgen co-founder Luis Branco said: “We are excited to add these remarkable diagnostic products to Zalgen's business, and we look forward to adding them to our expanding global distribution network.

“Zalgen has been active in the research and development of these products since our inception, and our new development site in Colorado will serve as the Company’s primary site for diagnostics, while our immunotherapeutics activities will remain centered in Maryland.”